768 related articles for article (PubMed ID: 24172895)
1. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity.
Okada-Iwabu M; Yamauchi T; Iwabu M; Honma T; Hamagami K; Matsuda K; Yamaguchi M; Tanabe H; Kimura-Someya T; Shirouzu M; Ogata H; Tokuyama K; Ueki K; Nagano T; Tanaka A; Yokoyama S; Kadowaki T
Nature; 2013 Nov; 503(7477):493-9. PubMed ID: 24172895
[TBL] [Abstract][Full Text] [Related]
2. The Adiponectin Receptor Agonist AdipoRon Ameliorates Diabetic Nephropathy in a Model of Type 2 Diabetes.
Kim Y; Lim JH; Kim MY; Kim EN; Yoon HE; Shin SJ; Choi BS; Kim YS; Chang YS; Park CW
J Am Soc Nephrol; 2018 Apr; 29(4):1108-1127. PubMed ID: 29330340
[TBL] [Abstract][Full Text] [Related]
3. AdipoR agonist increases insulin sensitivity and exercise endurance in AdipoR-humanized mice.
Iwabu M; Okada-Iwabu M; Tanabe H; Ohuchi N; Miyata K; Kobori T; Odawara S; Kadowaki Y; Yokoyama S; Yamauchi T; Kadowaki T
Commun Biol; 2021 Jan; 4(1):45. PubMed ID: 33420419
[TBL] [Abstract][Full Text] [Related]
4. Antidiabetic features of AdipoAI, a novel AdipoR agonist.
Ahuja A; Zboinski E; das S; Zhu X; Ma Q; Xie Y; Tu Q; Chen J
Cell Biochem Funct; 2024 Jan; 42(1):e3910. PubMed ID: 38269524
[TBL] [Abstract][Full Text] [Related]
5. Adiponectin receptor agonist ameliorates cardiac lipotoxicity via enhancing ceramide metabolism in type 2 diabetic mice.
Kim Y; Lim JH; Kim EN; Hong YA; Park HJ; Chung S; Choi BS; Kim YS; Park JY; Kim HW; Park CW
Cell Death Dis; 2022 Mar; 13(3):282. PubMed ID: 35351872
[TBL] [Abstract][Full Text] [Related]
6. AdipoRon, an Orally Active, Synthetic Agonist of AdipoR1 and AdipoR2 Receptors Has Gastroprotective Effect in Experimentally Induced Gastric Ulcers in Mice.
Zatorski H; Salaga M; Zielińska M; Majchrzak K; Binienda A; Kordek R; Małecka-Panas E; Fichna J
Molecules; 2021 May; 26(10):. PubMed ID: 34063466
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of Adiponectin Action: Implication of Adiponectin Receptor Agonism in Diabetic Kidney Disease.
Kim Y; Park CW
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30974901
[TBL] [Abstract][Full Text] [Related]
8. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
[TBL] [Abstract][Full Text] [Related]
9. Tiliroside, a glycosidic flavonoid, ameliorates obesity-induced metabolic disorders via activation of adiponectin signaling followed by enhancement of fatty acid oxidation in liver and skeletal muscle in obese-diabetic mice.
Goto T; Teraminami A; Lee JY; Ohyama K; Funakoshi K; Kim YI; Hirai S; Uemura T; Yu R; Takahashi N; Kawada T
J Nutr Biochem; 2012 Jul; 23(7):768-76. PubMed ID: 21889885
[TBL] [Abstract][Full Text] [Related]
10. AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis.
Xu H; Zhao Q; Song N; Yan Z; Lin R; Wu S; Jiang L; Hong S; Xie J; Zhou H; Wang R; Jiang X
Nat Commun; 2020 Nov; 11(1):5807. PubMed ID: 33199780
[TBL] [Abstract][Full Text] [Related]
11. Resveratrol increases AdipoR1 and AdipoR2 expression in type 2 diabetic nephropathy.
Park HS; Lim JH; Kim MY; Kim Y; Hong YA; Choi SR; Chung S; Kim HW; Choi BS; Kim YS; Chang YS; Park CW
J Transl Med; 2016 Jun; 14(1):176. PubMed ID: 27286657
[TBL] [Abstract][Full Text] [Related]
12. AdipoRon, the first orally active adiponectin receptor activator, attenuates postischemic myocardial apoptosis through both AMPK-mediated and AMPK-independent signalings.
Zhang Y; Zhao J; Li R; Lau WB; Yuan YX; Liang B; Li R; Gao EH; Koch WJ; Ma XL; Wang YJ
Am J Physiol Endocrinol Metab; 2015 Aug; 309(3):E275-82. PubMed ID: 26037251
[TBL] [Abstract][Full Text] [Related]
13. Activation of adiponectin receptors has negative impact on muscle mass in C2C12 myotubes and fast-type mouse skeletal muscle.
Ito R; Higa M; Goto A; Aoshima M; Ikuta A; Ohashi K; Yokoyama S; Ohno Y; Egawa T; Miyata H; Goto K
PLoS One; 2018; 13(10):e0205645. PubMed ID: 30308063
[TBL] [Abstract][Full Text] [Related]
14. Hepatoprotective effects of AdipoRon against d-galactosamine-induced liver injury in mice.
Wang Y; Wan Y; Ye G; Wang P; Xue X; Wu G; Ye B
Eur J Pharm Sci; 2016 Oct; 93():123-31. PubMed ID: 27516150
[TBL] [Abstract][Full Text] [Related]
15. Butyrate alleviates high fat diet-induced obesity through activation of adiponectin-mediated pathway and stimulation of mitochondrial function in the skeletal muscle of mice.
Hong J; Jia Y; Pan S; Jia L; Li H; Han Z; Cai D; Zhao R
Oncotarget; 2016 Aug; 7(35):56071-56082. PubMed ID: 27528227
[TBL] [Abstract][Full Text] [Related]
16. Adiponectin homolog novel osmotin protects obesity/diabetes-induced NAFLD by upregulating AdipoRs/PPARα signaling in ob/ob and db/db transgenic mouse models.
Ahmad A; Ali T; Kim MW; Khan A; Jo MH; Rehman SU; Khan MS; Abid NB; Khan M; Ullah R; Jo MG; Kim MO
Metabolism; 2019 Jan; 90():31-43. PubMed ID: 30473057
[TBL] [Abstract][Full Text] [Related]
17. Adiponectin receptor agonist AdipoRon decreased ceramide, and lipotoxicity, and ameliorated diabetic nephropathy.
Choi SR; Lim JH; Kim MY; Kim EN; Kim Y; Choi BS; Kim YS; Kim HW; Lim KM; Kim MJ; Park CW
Metabolism; 2018 Aug; 85():348-360. PubMed ID: 29462574
[TBL] [Abstract][Full Text] [Related]
18. Drug development research for novel adiponectin receptor-targeted antidiabetic drugs contributing to healthy longevity.
Okada-Iwabu M; Iwabu M; Yamauchi T; Kadowaki T
Diabetol Int; 2019 Oct; 10(4):237-244. PubMed ID: 31592400
[TBL] [Abstract][Full Text] [Related]
19. AdipoRon Protects Against Secondary Brain Injury After Intracerebral Hemorrhage via Alleviating Mitochondrial Dysfunction: Possible Involvement of AdipoR1-AMPK-PGC1α Pathway.
Yu J; Zheng J; Lu J; Sun Z; Wang Z; Zhang J
Neurochem Res; 2019 Jul; 44(7):1678-1689. PubMed ID: 30982205
[TBL] [Abstract][Full Text] [Related]
20. Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels.
Haluzik MM; Lacinova Z; Dolinkova M; Haluzikova D; Housa D; Horinek A; Vernerova Z; Kumstyrova T; Haluzik M
Endocrinology; 2006 Sep; 147(9):4517-24. PubMed ID: 16740970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
